A long-acting injectable (LAI) antipsychotic for the treatment of adults with schizophrenia1
All the information in this website is intended exclusively for Australian health care professionals and contains information pertaining to locally marketed products. Content regarding medication is informative. It is the responsibility of healthcare professionals to decide, on an individual basis, the most appropriate treatment to suit the needs of the patient.
Abilify Maintena PBS Information: Authority required (STREAMLINED). Code: 4246 for schizophrenia.
This product is not listed on the PBS for the treatment of bipolar 1 disorder.
Brintellix PBS information: This product is not listed on the PBS.
REXULTI PBS Information: Authority required (STREAMLINED). Code: 4246 for schizophrenia
Vyepti PBS Information: This product is not listed on the PBS.
Lexapro PBS Information: Restricted benefit.
Major Depressive Disorders, moderate to severe Generalised Anxiety Disorder, and moderate to severe Social Anxiety Disorder. Refer to PBS Schedule for full information.
Please review Approved Product Information before prescribing.
Product Information is available by calling Lundbeck on 1300 721 277 or by clicking:
References: 1. Abilify Maintena Australian Product Information. 2. Brintellix Australian Product Information. 3. REXULTI Australian Product Information. 4. Vyepti Australian Product Information. 5. Lexapro Australian Product Information
Abilify Maintena is a registered trademark of Otsuka Pharmaceutical Co., Ltd. Brintellix, REXULTI,Vyepti and Lexapro are registered trademarks of H. Lundbeck A/S. Abilify Maintena® and REXULTI® are co-commercialised by Lundbeck Australia and Otsuka Australia Pharmaceutical Pty Limited.
To gain access, please provide details to verify you are a healthcare professional.
Your privacy is important. When you register, we may collect your personal information such as your name and contact details, as outlined at 'Lundbeck and Privacy’ on our Progress in Mind website.